Crizotinib and Histrelin: Interaction Details
- Crizotinib
- Xalkori
- Histrelin
- Supprelin
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Crizotinib and Histrelin interaction:
Histrelin
- Supprelin
We don't have a drug information page for Histrelin yet. Have a question about Histrelin? Ask a pharmacist, free →
What Happens When You Take Crizotinib With Histrelin
What can happen when they are taken together (rated Major)
Increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Giving histrelin together with other drugs that prolong the produces effects on QT duration. Androgen deprivation from GnRH or can itself lengthen the QT interval.
In patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and in those receiving drugs known to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as histrelin outweigh the possible risks.3 Where possible, avoid using histrelin concurrently with agents that prolong QT. When cannot be avoided, do not use drugs that cause electrolyte disturbances (ie, or ),1 correct any existing electrolyte abnormalities, and consider periodic and electrolyte monitoring.3
The Crizotinib and Histrelin Interaction, Explained
Both of these medicines can affect your heart's electrical rhythm. Crizotinib (Xalkori) is a cancer medicine that can lengthen a part of the heartbeat called the . Histrelin (Supprelin) lowers androgen (male hormone) levels, and that can also lengthen the QT interval a little. Taken together, the effects may add up and raise the chance of an irregular heart rhythm. This concern is mostly based on how the drugs work, not on many reported cases.
Keep taking both as prescribed. Tell your pharmacist or doctor about any heart rhythm problems, fainting, or dizziness. Your care team can manage this by checking your heart tracing () and your potassium and magnesium levels.
(). Crizotinib is associated with QTc prolongation, and androgen deprivation therapy with GnRH such as histrelin may also prolong the . Evidence for this combination is theoretical; onset is unspecified. Severity on file: major.
- Weigh the benefit of ADT against risk, especially with congenital long QT syndrome, heart failure, or frequent electrolyte abnormalities.
- Avoid with QT-prolonging agents when possible.
- If coadministration is required, avoid drugs that cause or , and correct electrolyte abnormalities.
- Consider periodic and electrolyte monitoring.
See the 3 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Crizotinib and Histrelin Interact
The likely mechanism
How to Manage the Crizotinib and Histrelin Interaction
Keep taking both medicines as prescribed unless your doctor tells you otherwise. Do not stop or change either one on your own.
- Your care team will weigh the benefits of each medicine against the heart rhythm risk, especially if you have heart failure, a long QT history, or often have low potassium or magnesium.
- They may check and correct your electrolytes and may monitor you more closely with periodic ECGs.
- They may try to avoid adding other medicines that affect heart rhythm or electrolytes.
- Tell your pharmacist or prescriber about all your medicines, and report fainting, palpitations, or severe dizziness right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Crizotinib or Histrelin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes
A study of male patients receiving androgen deprivation therapy (ADT) analyzed individual case safety reports in VigiBase, the international pharmacovigilance database, and identified 184 cases of acquired long-QT syndrome (aLQTS) and/or (TdP; 11% fatal) and 99 cases of sudden death associated with ADT. Most ADT-associated cases of aLQTS/TdP (62%) and sudden death (88%) occurred without exposure to other drugs known to raise TdP risk.
Exposure to 1 drug, or to 2 or more drugs, with conditional, possible, or known TdP risk was nonetheless reported in some aLQTS/TdP events (23% or 43%) and some sudden death events (18% and 22%). The drugs classed as ADTs were abiraterone, gonadotropin-releasing hormone and , nonsteroidal androgen receptor indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism.
Among the 10 ADTs evaluated, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death: leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was about 76 years.
Median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were receiving ADT mainly for prostate cancer, and some were treated for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%), while 17% were receiving ADT combination therapy.2
Crizotinib and Histrelin: Common Questions
How serious is the Crizotinib and Histrelin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Crizotinib and Histrelin interaction managed?
Keep taking both medicines as prescribed unless your doctor tells you otherwise. Do not stop or change either one on your own. Your care team will weigh the benefits of each medicine against the heart rhythm risk, especially if you have heart failure, a long QT history, or often have low potassium or magnesium. They may check and correct your electrolytes and may monitor you more closely with peri… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Crizotinib and Histrelin Interaction
Ask in your own words about taking Crizotinib and Histrelin together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (3)
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
- Product Information: VANTAS® subcutaneous implant, histrelin acetate subcutaneous implant. Endo Pharmaceuticals Solutions Inc, Malvern, PA, 2026. DailyMed
Other Serious Interactions of Crizotinib and Histrelin
Also serious with Crizotinib
- Ketoconazole TopicalContraindicated
- CobicistatContraindicated
- Cobicistat / Darunavir EthanolateContraindicated
- AtazanavirContraindicated
Also serious with Histrelin
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Crizotinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 154 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.